Search
Insilico Medicine: Releases Initial Promising Data from Phase I First-in-Human Clinical Trial of ISM6331
1 day ago /
Read about 0 minute
Author：小编
Insilico Medicine made an announcement on the Hong Kong Stock Exchange, stating that at the 2026 Annual Congress of the European Society for Medical Oncology (ESMO), the company shared, through a proffered paper session, the initial promising data from the Phase I first-in-human clinical trial of ISM6331. ISM6331 is an investigational oral pan-TEAD inhibitor that has been developed using the Chemistry42 generative AI platform. As of August 14, 2026, among the mesothelioma patients whose treatment efficacy could be evaluated, the objective response rate (ORR) stood at 40% in the group receiving a daily dose of 130mg. Moreover, within the dose range of 30–130mg, the disease control rate (DCR) at the first tumor assessment was 68.2%.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
